Greg has over 20 years of experience in the clinical development industry, having held strategic leadership positions in industry-leading drug/device and CRO companies. Prior to Noxopharm, Greg was the founder and CEO of DZS Clinical Services, Inc., a CRO focused on supporting small to mid-size biotech organizations.
During his tenure at DZS, the company achieved consistent growth and expansion, resulting in multiple regulatory approvals globally and significant commercial success. Greg supported the successful sale of the company's proprietary software platform in 2017 and continued to lead the services organization through a successful acquisition by WDB Medical Group in 2018. Greg previously held various leadership positions at Baxter Healthcare, Convatec, and Campbell Alliance, a leading life sciences management consultant group.
Greg has a passion for bringing new therapeutics to patients by fostering a sense of urgency and a culture of excellence. He holds a master's degree in Medical Sciences from Boston University and is currently finalizing an MBA from William and Mary College.